Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Part A and B:~* Subject is male or female between 2 and 14 months of age~* The diagnosis of infantile spasms (IS)~* Subject has drug-resistant IS~Part C:~* Subject participated in EP0078 Part A and received 2 radiprodil treatment cycles~* Subject experienced a relapse of spasms during the down taper or within 5 half-lives (3 days) discontinuation of radiprodil treatment in Cycle 2 of Part A~* Electroencephalogram (EEG) on baseline Part C is compatible with the diagnosis of infantile spasms~Exclusion Criteria:~Part A and B:~* More than 6 months have passed since the diagnosis of Infantile Spasms (IS)~* Current treatment with cannabinoids~* Subject has hematocrit greater than 60~* Subject has any medical condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study~* Subject has a history or current condition predisposing to respiratory dysfunction~* Current treatment with felbamate~* Current treatment with perampanel~* Ketogenic diet~* Clinically significant lab abnormalities~* Clinically significant abnormality on ECG that, in the opinion of the Investigator, increases the safety risks of participating in the study~* Subject has a lethal or potentially lethal condition other than IS, with a significant risk of death before 18 months of age such as non-ketotic hyperglycinemia~* Body weight is below 4 kg~* Known history of severe anaphylactic reaction secondary to medication intake or serious blood dyscrasias~Part C:~* Subject experienced any acute tolerability issues in either treatment cycle in Part A which the investigator and the sponsor medical monitor consider a risk for further participation~* Subject met any withdrawal criteria in Part A~* Subject has experienced any adverse effects or developed any new medical conditions since enrollment in Part A which the investigator considers could significantly increase the safety risks of participating in Part C

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 14 Months
- Healthy Volunteers: f

Study Arms:
- Radiprodil (Type: EXPERIMENTAL): Each subject will enter an individualized dose titration schedule.

Based on this trial design, predict the completion outcome and termination type (if applicable).